

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai MicroPort MedBot (Group) Co., Ltd.**

**上海微创医疗机器人(集团)股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2252)**

**VOLUNTARY ANNOUNCEMENT — BUSINESS UPDATE  
AND  
ANNOUNCEMENT MADE PURSUANT TO RULES 13.51B(2) AND  
13.51(2)(H) OF THE LISTING RULES**

**BUSINESS UPDATE**

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”), and the Company is pleased to announce that, according to preliminary internal statistics of the Company, as of the date of this announcement, the cumulative order volume of the Group’s laparoscopic, orthopedic and vascular interventional core products has exceeded 130 units. Among them, Toumai Laparoscopic Surgical Robot (“**Toumai**”) has received more than 70 cumulative commercial orders worldwide (nearly 20 new commercial orders were received globally in 2025), and the cumulative number of commercial installations has exceeded 50 units. Meanwhile, Toumai has continuously accelerated the development of large-scale, normalized clinical applications. To date, the number of human clinical surgeries performed by Toumai worldwide has exceeded 10,000 cases.

In terms of product registration, since 2025 and as of the date of this announcement, Toumai has obtained registration certification in more than 10 countries or regions, cumulatively more than 30 countries or regions worldwide. The clinical efficacy, stability, safety, innovation level, and technical content of Toumai are being increasingly recognised by international authoritative regulatory agencies. SkyWalker Orthopedic Surgical Robot obtained registration approval from Health Canada in January 2025, further expanding its development layout in the global mainstream orthopedic surgical robot market.

Following the global first registration approval for the full-department remote surgery application of Toumai in April 2025, the Company has continued to explore advancements in the clinical application of remote surgery. Recently, Toumai has assisted Belgian surgical experts in successfully completing two consecutive remote surgeries, marking the first robot-assisted remote human surgeries in Europe. These surgeries utilised the hospital's conventional network (V-LAN) transmission pathway, with a bidirectional latency of only 20 milliseconds, fully ensuring the technical requirements of millisecond-level accuracy required for remote robotic surgery. This further demonstrated the advanced nature of remote surgery technology systems used by Toumai, including image low-latency ultra-compression technology, multi-dimensional data encryption technology, dynamic communication network optimization strategy, and surgical safety assurance mechanism in complex network environments.

The above information is provided by the Company on a voluntary basis to provide the shareholders of the Company (the “**Shareholders**”) and potential investors with the update on the latest business development of the Group.

**The board of directors of the Company (the “Board”) wishes to remind the Shareholders and potential investors that the above information is unaudited and is based on preliminary internal information of the Group, which may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company on an annual or half-yearly basis due to various uncertainties during the process of collating such information.**

**The Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

#### **ANNOUNCEMENT MADE PURSUANT TO RULES 13.51B(2) AND 13.51(2) (H) OF THE LISTING RULES**

The following is provided pursuant to Rules 13.51B(2) and 13.51(2)(h) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). Reference is made to the regulatory announcement dated 11 June 2025 (the “**Regulatory Announcement**”) issued by the Stock Exchange in relation to the disciplinary action taken by the Stock Exchange against New Century Healthcare Holding Co. Limited (a company listed on the Stock Exchange, stock code: 1518) (“**New Century Healthcare**”) and its certain existing and former directors (including, among others, Mr. Sun Hongbin (“**Mr. Sun**”), a non-executive director of the Company).

According to the Regulatory Announcement, New Century Healthcare was reprimanded by the Stock Exchange for its connected persons' overdue or failure of payment of service fees to New Century Healthcare. The Listing Committee of the Stock Exchange criticised independent non-executive directors of New Century Healthcare, including, among others, Mr. Sun, and has directed Mr. Sun to attend 15 hours of training on regulatory and legal topics, including compliance with the Listing Rules, directors' duties and the Corporate Governance Code.

To the best of the knowledge, information and belief of the Board, the matters contained in the Regulatory Announcement are irrelevant to the affairs of the Group and will not have any impact on the Group. The Board recognises that Mr. Sun has been diligently contributing to the Company since his appointment as a non-executive director of the Company. There is no finding or conclusion in the Regulatory Announcement that Mr. Sun is not suitable to be a director of a Hong Kong listed company, and therefore it will not affect Mr. Sun's performance of his duties as a non-executive director of the Company.

Save as disclosed in the Regulatory Announcement and this announcement, there is no other information relating to Mr. Sun that is required to be disclosed pursuant to Rule 13.51B(2) of the Listing Rules, and there are no other matters relating to Mr. Sun's serving as a director of the Company that need to be brought to the attention of the Shareholders of the Company and the Stock Exchange.

By order of the Board  
**Shanghai MicroPort MedBot (Group) Co., Ltd.**  
**Dr. He Chao**  
*Executive Director*

Shanghai, China, 12 June 2025

*As at the date of this announcement, the executive directors are Dr. He Chao and Ms. Fang Cong; the non-executive directors are Mr. Sun Hongbin and Mr. Chen Chen; and the independent non-executive directors are Dr. Li Minghua, Mr. Yao Haisong and Mr. Chung Wai Man.*